GLP-1 Agonist Therapy in a Patient With T2D and CVD

April 15, 2019 3:54 pm

Recommendations for initiating therapy with a GLP-1 receptor agonist in a 46-year-old woman with type 2 diabetes as well as hypertension and hypercholesterolemia, and insight regarding patient and physician misconceptions surrounding the prescribing and utilization of injectables.

Category: News
About The Author
-
Previous

[Preview] A low-carb diet for T2D reversal – Dr. Sarah Hallberg
Next

Mechanisms of Action of GLP-1 Agonists in T2D

Related Videos

Unleashing-the-Truth-How-to-Put-T2D-Patients-Hearts-First

Unleashing the Truth: How to Put T2D Patients’ Hearts First

Low-carb-for-diabetes-A-transformation-Diet-Doctor-Podcast

Low carb for diabetes: A transformation — Diet Doctor Podcast

Diabetes-debunked-Fact-vs.-fiction-on-ways-to-prevent-manage-and-reverse-the-disease

Diabetes debunked: Fact vs. fiction on ways to prevent, manage, and reverse the disease

Type-2-Diabetes-Treatments-1

A Data Integration Multi-Omics Approach to Study Calorie Restriction-Induced Changes in Insulin Sensitivity

4-simple-tips-to-reverse-Type-2-Diabetes

4 simple tips to reverse Type 2 Diabetes

Diabetologists-Perspective-of-Diabetes-and-Cardiovascular-Risk-Management-in-Post-ACS-T2D-patients

Diabetologist’s Perspective of Diabetes and Cardiovascular Risk Management in Post-ACS T2D patients